Jefferies Financial Group Inc. Invests $574,000 in Dianthus Therapeutics, Inc. $DNTH

Jefferies Financial Group Inc. purchased a new stake in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) during the second quarter, Holdings Channel.com reports. The institutional investor purchased 5,886 shares of the company’s stock, valued at approximately $574,000.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. BlackRock Inc. acquired a new position in Dianthus Therapeutics during the 2nd quarter valued at about $401,990,000. Wellington Management Group LLP raised its position in shares of Dianthus Therapeutics by 3,366.9% during the 3rd quarter. Wellington Management Group LLP now owns 2,577,662 shares of the company’s stock worth $101,431,000 after buying an additional 2,503,311 shares in the last quarter. Vestal Point Capital LP lifted its stake in shares of Dianthus Therapeutics by 88.2% in the 2nd quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company’s stock worth $59,616,000 after acquiring an additional 1,499,931 shares during the period. State Street Corp lifted its stake in shares of Dianthus Therapeutics by 124.7% in the 4th quarter. State Street Corp now owns 1,507,619 shares of the company’s stock worth $62,129,000 after acquiring an additional 836,571 shares during the period. Finally, Polar Capital Holdings Plc acquired a new stake in shares of Dianthus Therapeutics in the 3rd quarter worth approximately $29,434,000. 47.53% of the stock is currently owned by institutional investors.

Insider Transactions at Dianthus Therapeutics

In other Dianthus Therapeutics news, Director Simon Read sold 2,778 shares of the company’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $117.55, for a total value of $326,553.90. Following the transaction, the director owned 2,778 shares of the company’s stock, valued at approximately $326,553.90. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Ryan Savitz sold 31,249 shares of the stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $101.03, for a total value of $3,157,086.47. Following the sale, the executive vice president owned 31,249 shares of the company’s stock, valued at $3,157,086.47. This trade represents a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 260,554 shares of company stock valued at $27,211,775 in the last 90 days. 3.02% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of research analysts recently commented on DNTH shares. HC Wainwright raised their price objective on shares of Dianthus Therapeutics from $130.00 to $158.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Wolfe Research reissued an “outperform” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Wedbush upped their target price on Dianthus Therapeutics from $105.00 to $122.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 5th. Raymond James Financial reaffirmed a “strong-buy” rating and set a $131.00 price target on shares of Dianthus Therapeutics in a research note on Wednesday, August 5th. Finally, TD Cowen reiterated a “buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Dianthus Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $124.27.

Dianthus Therapeutics Price Performance

Shares of DNTH opened at $105.61 on Tuesday. The firm’s 50 day moving average is $103.96 and its 200-day moving average is $87.71. The stock has a market capitalization of $5.77 billion, a P/E ratio of -25.45 and a beta of 1.22. Dianthus Therapeutics, Inc. has a 12-month low of $22.81 and a 12-month high of $117.88.

Dianthus Therapeutics (NASDAQ:DNTH) last released its earnings results on Tuesday, August 4th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.05). The business had revenue of $0.76 million for the quarter, compared to analyst estimates of $0.30 million. Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative return on equity of 22.53%. As a group, equities research analysts forecast that Dianthus Therapeutics, Inc. will post -3.83 EPS for the current fiscal year.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.